Open Trials at PCC

Available Clinical Trials at Pacific Cancer Care

Pacific Cancer Care is driven by a vision to be the leader for the treatment of cancer in the Monterey County. Our clinicians and investigators identify and conduct Phase I-IV treatment options that are new and innovative, and that will positively impact our patients. Below is a list of clinical trials currently available at Pacific Cancer Care.

For more information regarding clinical trial opportunities, please contact Monica Castillo, Clinical Research Manager, at [email protected] or call her at (831) 375-4105 ext. 1077

Advanced Unresectable or Metastatic Solid Malignancy
NCT #04632992
MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations Or Protein Expression Patterns Predictive or Response

Colorectal Cancer
NCT #04776148
LEAP-017: A Phase 3 Randomized Study of Lenvatinib in Combination with Pembrolizumab Versus Standard of Care in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed Through or Became Intolerant to Prior Treatment

Gastric or Gastroesophageal Junction (GEJ)
NCT #03653507
Glow: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Hematologic Malignancies
NCT #03598608
MK4280-003: A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab in Participants with Hematologic Malignancies

Hematologic Malignancies
NCT #03893682
Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin’s Lymphomas

Multiple Myeloma
NCT #03110822
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients

Non-small Cell Lung Cancer
NCT #03425643
Keynote-671: A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer

Triple Negative Breast Cancer
NCT #04191135
KEYLYNK-009: An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit with First-line Chemotherapy Plus Pembrolizumab in Participants with Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer and Bladder Cancer
NCT #03961698
MARIO-3: A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma

Through partnerships with organizations such as the Dana Farber Cancer Institute and Parker Institute for Cancer Immunotherapy, our patients rest assured knowing that a full complement of research and clinical resources are available to them, all synchronized and supervised by their Pacific Cancer Care team.